1. Apperley J (2002) A rationally designed, targeted tumor treatment approach: a phase II study of imatinib mesylate (Gleevec) in patients with life threatening diseases known to be associated with imatinib-sensitive tyrosine kinases. Proc Am Soc Clin Oncol 21:3a
2. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502
3. Corless CL, McGreevey L, Haley A, Town A, Heinrich M (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimetre or less in size. Am J Pathol 160:1567–1572
4. Demetri GD, Rankin C, Fletcher C, Benjamin RS, Blanke C, Von Mehren M, Bramwell V, Maki RG, Blum R, Antman K, Baker L, Borden E (2002a) Phase III dose-randomized study of imatinib mesylate (gleevec, STI571) for GIST: intergroup S0033 early results. Proc Am Soc Clin Oncol 21:413a
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002b) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 347:472–480